Nuvation Bio’s first marketed cancer drug could grow only if more patients get the right kind of genetic testing, and that shift is still playing out. Meanwhile, its next big brain cancer program may take years to read out, leaving investors weighing a long wait against the chance of a second meaningful product.Read more
Nuvation Bio is betting that one lung cancer drug can keep winning patients as testing improves and the company expands into new countries. A second brain cancer program could add another growth engine, but it takes years to prove out and leaves the company exposed if competition or access hurdles slow momentum.Read more
Nuvation Bio’s lung cancer drug is gaining traction, and wider testing could help more patients get diagnosed and treated over time. The bigger question is whether its next program in brain cancer can deliver on a long, slow timeline while competition and global pricing decisions shape how far growth can go.Read more
No trending discussion available.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
